Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Immunochemicals Find Increased Applications - Increasing demand from a range of areas including healthcare, agriculture and counter bio-terrorism are set to drive the global immunochemicals market
Immunochemicals Find Increased Applications


PRZOOM - /newswire/ - London, United Kingdom, 2008/03/18 - Increasing demand from a range of areas including healthcare, agriculture and counter bio-terrorism are set to drive the global immunochemicals market.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


New analysis from Frost & Sullivan (, Global Immunochemicals Markets, finds that the market earned revenues of $1.50 billion in 2007 and estimates this to reach $2.60 billion in 2014.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the Global Immunochemicals Markets, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.], with your full name, company name, title, telephone number, fax number, and email address. Upon receipt of the above information, an overview will be sent to you by email.

"The mounting demand for cancer research has been a crucial driving factor for the immunochemicals market globally," notes Frost & Sullivan Industry Analyst Sylvia Miriam Findlay. "Research antibodies have been used as tools in various applications, including signalling pathways, measuring the modifications or expression levels of cancer-related proteins, identifying candidate biomarkers, profiling proteins and measuring enzyme activity."

In other areas, research on improving food production, enhancing food quality and nutrition and producing pharmaceutical and industrial products through genetically engineered plants has received significant attention. Bio-terrorism has also motivated the search for effective tools to detect dangerous toxins. Antibody assays for cholera toxin, diphtheria toxin and anthrax are being developed for use in a law enforcement setting.

However, the market is unlikely to be very lucrative, particularly for new entrants, since it is anticipated to be stagnant over the long-term. This is primarily because two-thirds of the currently available antibodies will be overhauled over the next five to seven years. Moreover, there will be constant changes in antibody targets due to ongoing proteome research.

"Promisingly, however, proteome research and the genome project will create growth opportunities with the discovery of newer proteins motivating manufacturers to augment their store of novel antibodies," explains Findlay. "Custom antibodies are gaining importance due to proteomics research."

In spite of being highly fragmented, with over 300 active companies, the immunochemicals market is dynamic and evolving. The future is likely to witness signficant restructuring with a spate of consolidations among market participants.

Fierce rivalries have led to competitive pricing and low revenue generation. Market shares are being diluted leaving the market landscape more open to mergers. Frost & Sullivan anticipates that publicly held companies will redefine laws by acquiring private companies.

The profusion of antibodies available is another challenge the market needs to address. Researchers are unable to browse through the enormous number of companies and their offerings to acquire their desired antibodies. The large selection of antibodies available makes it difficult for researchers to review and identify the most suitable antibody for their use.

"There is a no common catalogue listing suppliers and the antibodies they offer," adds Findlay. "The process of forming a common catalogue is highly complicated as it requires the integration of data of thousands of antibodies from hundreds of suppliers."

The introduction of a common catalogue providing details about various companies, products, offers, prices and contacts would be ideal in widening the customer base. This strategy would facilitate the use of research antibodies and boost market revenues.

Global Immunochemicals Markets is part of the Pharmaceutical and Clinical Diagnostics Growth Partnership Service Programme, which also includes research in the following markets: European Biosimilars Market and European Head and Neck Cancer Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Global Immunochemicals Markets - M1E4

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: Frost & Sullivan


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Immunochemicals Find Increased Applications

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Patrick Cairns 
+27 18 468 2315 patrick.cairns[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Press Releases From Frost & Sullivan / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



Visit  MagLar, Inc.

Visit  Intrinsic Executive Search Ltd

  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today